The influence of THCCBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.
Driving ability is a key function for the majority of patients with multiple sclerosis (MS) to help maintain daily interactions. Both physical and cognitive disability, as well as treatments, may affect the ability to drive. Spasticity is a common symptom associated with MS, and it may affect driving performance either directly or via the medications used to treat it. In this article, we review the evidence relating the antispasticity medicine, Δ Articles were identified by searching PubMed from 112000 to 3062017 using a specified list of search terms. The articles identified using these search terms were augmented with relevant references from these papers and other articles known to the authors. The results from THCCBD oromucosal spray driving studies and real-world registries did not show any evidence of an increase in motor vehicle accidents associated with THCCBD oromucosal spray. The majority of patients reported an improvement in driving ability after starting THCCBD oromucosal spray, and it was speculated that this may be related to reduced spasticity andor better cognitive function. It should be noted that THC blood levels are significantly lower than the levels associated with recreational use of herbal cannabis. THCCBD oromucosal spray was shown not to impair driving performance. However, periodic assessment of patients with MS driving ability is recommended, especially after relapses and changes in treatment. Blood THC measurements might be above authorized thresholds for some countries following administration of THCCBD oromucosal spray, thus specific knowledge of each countrys driving regulations and a medical certificate are recommended.